Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2019 1
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM. Jiang YZ, et al. Cancer Cell. 2019 Mar 18;35(3):428-440.e5. doi: 10.1016/j.ccell.2019.02.001. Epub 2019 Mar 7. Cancer Cell. 2019. PMID: 30853353 Free article.
We comprehensively analyzed clinical, genomic, and transcriptomic data of a cohort of 465 primary triple-negative breast cancer (TNBC). PIK3CA mutations and copy-number gains of chromosome 22q11 were more frequent in our Chinese cohort than in T …
We comprehensively analyzed clinical, genomic, and transcriptomic data of a cohort of 465 primary triple-negative
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Lehmann BD, et al. Nat Commun. 2021 Nov 1;12(1):6276. doi: 10.1038/s41467-021-26502-6. Nat Commun. 2021. PMID: 34725325 Free PMC article.
Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers characterized by distinct transcriptional patterns, biology, and immune composition. ...Subtype-specific differences in immune cell composition and differential
Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers characterized by distinct t
Locoregional recurrence in triple negative breast cancer: past, present, and future.
Tran J, Thaper A, Lopetegui-Lia N, Ali A. Tran J, et al. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1085-1093. doi: 10.1080/14737140.2023.2262760. Epub 2023 Oct 26. Expert Rev Anticancer Ther. 2023. PMID: 37750222 Review.
INTRODUCTION: Triple negative breast cancer (TNBC) is a rare but aggressive biological subtype of breast cancer associated with higher locoregional and distant recurrence rates and lower overall survival despite advancements in diagnostic and …
INTRODUCTION: Triple negative breast cancer (TNBC) is a rare but aggressive biological subtype of breast
Targeting a cell state common to triple-negative breast cancers.
Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM. Muellner MK, et al. Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664. Mol Syst Biol. 2015. PMID: 25699542 Free PMC article.
Some mutations in cancer cells can be exploited for therapeutic intervention. However, for many cancer subtypes, including triple-negative breast cancer (TNBC), no frequently recurring aberrations could be identified to make such an approach clinically …
Some mutations in cancer cells can be exploited for therapeutic intervention. However, for many cancer subtypes, including triple
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Miyashita M, Bell JSK, Wenric S, Karaesmen E, Rhead B, Kase M, Kaneva K, De La Vega FM, Zheng Y, Yoshimatsu TF, Khramtsova G, Liu F, Zhao F, Howard FM, Nanda R, Beaubier N, White KP, Huo D, Olopade OI. Miyashita M, et al. Breast Cancer Res. 2023 May 25;25(1):58. doi: 10.1186/s13058-023-01627-2. Breast Cancer Res. 2023. PMID: 37231433 Free PMC article.
BACKGROUND: Endocrine-resistant HR+/HER2- breast cancer (BC) and triple-negative BC (TNBC) are of interest for molecularly informed treatment due to their aggressive natures and limited treatment profiles. ...These findings could guide future de …
BACKGROUND: Endocrine-resistant HR+/HER2- breast cancer (BC) and triple-negative BC (TNBC) are of interest for molecula …